Invention Grant
- Patent Title: Therapy for transthyretin-associated amyloidosis
-
Application No.: US14353459Application Date: 2012-10-23
-
Publication No.: US09610270B2Publication Date: 2017-04-04
- Inventor: Marc Centellas Casado , Raúl Insa Boronat , Nuria Reig Bolaño , Núria Gavaldà Batalla
- Applicant: SOM INNOVATION BIOTECH, S.L.
- Applicant Address: ES Barcelona
- Assignee: SOM INNOVATION BIOTECH, S.L.
- Current Assignee: SOM INNOVATION BIOTECH, S.L.
- Current Assignee Address: ES Barcelona
- Agency: Jenkins, Wilson, Taylor & Hunt
- Priority: EP11382326 20111024
- International Application: PCT/EP2012/070945 WO 20121023
- International Announcement: WO2013/060668 WO 20130502
- Main IPC: A61K31/42
- IPC: A61K31/42 ; A61K31/165 ; A61K31/12 ; A61K31/198 ; A61K45/06 ; A61K31/353 ; A61K31/423 ; A61K31/603 ; A61K31/192
Abstract:
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Public/Granted literature
- US20140296188A1 NEW THERAPY FOR TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS Public/Granted day:2014-10-02
Information query
